InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by Kwan Rudolf, Vice-Président Exécutif, Médecin en Chef. Officer active across 1 companies, notably Athenex, Inc.. In total, 11 reports have been recorded. Total volume traded: €14k. The latest transaction was disclosed on 17 June 2022 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations11 total
€11,49224,832 shares@ €0.46284.9% of flow
Common Stock
SEC:0001209191-22-038387:0·
€4,5589,927 shares@ €0.45911.9% of flow
Common Stock
SEC:0001209191-22-034502:0·
€4,63210,137 shares@ €0.45692.0% of flow
Common Stock
SEC:0001209191-22-031317:0·
€4,64910,107 shares@ €0.462.0% of flow
Common Stock
SEC:0001209191-22-027630:0·
€4,5237,986 shares@ €0.56631.9% of flow
Common Stock
SEC:0001209191-22-026250:0·
€4,5106,516 shares@ €0.69211.9% of flow
Common Stock
SEC:0001209191-22-024048:0·
€4,4515,422 shares@ €0.82091.9% of flow
Common Stock
SEC:0001209191-22-021498:0·
€7,2144,000 shares@ €1.80357.4% of flow
Common Stock
SEC:0001209191-21-065085·
Ideal exit: 13 Aug 2022 (T+270)
€7,2144,000 shares@ €1.80353.1% of flow
Common Stock
SEC:0001209191-21-065085:0·
Ideal exit: 13 Aug 2022 (T+270)
€90,48324,000 shares@ €3.770192.6% of flow
Common Stock
SEC:0001209191-21-030958·
€90,48324,000 shares@ €3.770138.6% of flow
Common Stock
SEC:0001209191-21-030958:0·
11 of 11 declarations
About Kwan Rudolf
Kwan Rudolf serves as Executive Vice President and Chief Medical Officer at Athenex, Inc. In this role, he oversees the company's medical and clinical initiatives, focusing on innovation in treatment development. His medical and scientific expertise enables him to lead critical research projects and collaborate with multidisciplinary teams. Kwan Rudolf is committed to advancing Athenex's mission of improving patient care.
